A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

Summary

Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

Timeline

Start

2017-05-31

Primary completion

2017-08-02

Completion

2017-08-02

Publications

• Couroux P, Farias P, Rizvi L, Griffin K, Hudson C, Crowder T, Tarran R, Tullis E. First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis. Pulm Pharmacol Ther. 2019 Oct;58:101819. doi: 10.1016/j.pupt.2019.101819. Epub 2019 Jul 11.

Drugs

Indications